In the context of metastatic prostate cancer, elevated GLO-1 expression can contribute to the establishment of an immunosuppressive microenvironment, promoting the upregulation of programmed death ligand 1 (PD-L1) expression, a process mediated by 5-hydro-5-methylimidazolone. Here, CD274 is linked to metastatic prostate carcinoma.